On August 10, JOINN rose 5.24% in regular trading, trading at HK$28.7/share, with turnover of HK$140 million. The gain was primarily driven by continued strength across the Life Sciences Tools and Services sector.

On the news front, the CXO sector extended its rally with WuXi AppTec up 3.85%, WuXi Biologics up 4.58%, and GenScript Biotech up 4.96%. The sector-wide momentum was fueled by WuXi AppTec's disclosed half-year results showing revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39%, alongside a full-year guidance upgrade that continues to bolster CXO sector sentiment.

Additionally, JOINN itself recently issued a strong half-year earnings forecast, projecting attributable net profit of RMB 600 million to RMB 900 million, representing growth of 885% to 1,377% year-over-year, primarily driven by biological asset fair value gains of RMB 703 million to RMB 777 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)